Variation in Early Anakinra Use and Short‐Term Outcomes in Multisystem Inflammatory Syndrome in Children
15 Citations•2023•
Joyce C. Chang, C. C. Young, E. Muscal
Arthritis & Rheumatology
Variation in initial treatment with anakinra is characterized and cardiovascular outcomes associated with adding anakinRA to standard initial therapy are evaluated.
Abstract
Evidence regarding effectiveness of interleukin‐1 receptor antagonism in multisystem inflammatory syndrome in children (MIS‐C) is lacking. We characterized variation in initial treatment with anakinra and evaluated cardiovascular outcomes associated with adding anakinra to standard initial therapy.